A Phase I, Two-part Study to Investigate the Effects of Food on the PK, Safety and Tolerability of a Single Oral Dose of AZD5069 (120 mg) in Healthy Adult Volunteers (Part A) and to Compare the PK of AZD5069 in Adult and Elderly Healthy Volunteers (Part B).
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs AZD 5069 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 16 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.